Pedro Isaacsson Velho

Pedro Isaacsson Velho

Auto-generated profile, based on publicly available information

Pedro Isaacsson Velho

Hospital Moinhos de Vento, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in European Urology
Verified
Journal Article
Closed access
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
FSFarah Shaukat
Farah Shaukat
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
HKHarsimar Kaur
Harsimar Kaur
ESEugene Shenderov
Eugene Shenderov
TLTamara L. Lotan
Tamara L. Lotan

25 January 2018 in The Prostate
Verified
Journal Article
Closed access
PDF file
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
JSJohn L. Silberstein
John L. Silberstein
MMMark C. Markowski
Mark C. Markowski
JLJun Luo
Jun Luo
TLTamara L. Lotan
Tamara L. Lotan
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis

29 March 2018 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
Introduction: Pharmacological inhibition of immune checkpoint receptors or their ligands represents a transformative breakthrough in the management of multiple cancers. However, immune checkpoint inhibitors have yet to be FDA-approved for the management of metastatic prostate cancer (PCa), the commonest non-cutaneous malignancy in men. Areas covered: We review our current understanding of the PD-1/PD-L1 pathway in cancer, the use of anti-PD-1/PD-L1 therapeutics in PCa, and potential subgroups of PCa patients who may derive the greatest benefit from these agents (such as men with tumors that have expression of PD-L1 and/or high mutational load). We also review the prior and current clinical trials evaluating the blockade of PD-1/PD-L1 in PCa, highlighting some of the key ongoing studies of greatest relevance to the field. Expert commentary: Clinical trials investigating PD-1/PD-L1 inhibitors should be encouraged in patients with PCa. While it is unlikely that immune checkpoint monotherapies will produce long-lasting responses in a substantial proportion of patients, there is early evidence of activity in some patient subsets. These subgroups may include those with high PD-L1 expression, those with hypermutated or microsatellite-unstable tumors, and those enriched for germline and/or somatic DNA-repair gene mutations (e.g. intraductal/ductal histology, primary Gleason pattern 5, and perhaps AR-V7-positive tumors).

1 June 2021 in European Urology Oncology
Verified
Journal Article
Closed access
MDMatthew P. Deek
Matthew P. Deek
KTKekoa Taparra
Kekoa Taparra
RPRyan Phillips
Ryan Phillips
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
RGRobert W. Gao
Robert W. Gao
BSBradley J. Stish
Bradley J. Stish

1 August 2019 in European Urology
Verified
Journal Article
Closed access
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
FQFahad Qazi
Fahad Qazi
SHSayeedul Hassan
Sayeedul Hassan
MCMichael A. Carducci
Michael A. Carducci
SDSamuel R. Denmeade
Samuel R. Denmeade
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis

1 January 2020 in European Urology
Verified
Journal Article
Closed access
PVPedro Isaacsson Velho
Pedro Isaacsson Velho
WFWei Fu
Wei Fu
HWHao Wang
Hao Wang
NMNooshin Mirkheshti
Nooshin Mirkheshti
FQFahad Qazi
Fahad Qazi
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis